Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs Follow-up in BPD
NCT03873506Phase 1Unknown
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in bronchopulmonary dysplasia (BPD), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Readmission rate at 2 years and Duration of the hospital stay due to respiratory infection at 2 years. Status: unknown.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03873506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873506.